Estradiol and dydrogesterone. A review of their combined use as hormone replacement therapy in postmenopausal women

Drugs and Aging

Volumn 11, Issue 4, 1997, Pages 309-332

  Foster, Rachel H ^a   Balfour, Julia A ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

DYDROGESTERONE; ESTRADIOL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TIBOLONE;

AMINO ACID BLOOD LEVEL; BLOOD PRESSURE MEASUREMENT; BODY WEIGHT; BODY WEIGHT DISORDER; BONE DENSITY; BONE MINERAL; BREAST CANCER; CANCER RISK; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLIMACTERIUM; CLINICAL TRIAL; DEPRESSION; DRUG TOLERABILITY; EDEMA; ENDOMETRIUM CANCER; ENDOMETRIUM HYPERPLASIA; FEMALE; HEADACHE; HEART PALPITATION; HORMONE SUBSTITUTION; HUMAN; INSULIN RESISTANCE; LUMBAR SPINE; MASTALGIA; MOUTH ULCER; NAUSEA; NEUROLOGIC DISEASE; ORAL DRUG ADMINISTRATION; POSTMENOPAUSE; PRIORITY JOURNAL; REVIEW; SKIN MANIFESTATION; TRANSDERMAL DRUG ADMINISTRATION; VAGINA BLEEDING;

EID: 0030722322     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-199711040-00006     Document Type: Review

References (107)

1. Pabst G, Brandenburg D, Strobel W. A study for evaluation of pharmacokinetic parameters of different 17β-estradiol, dydrogesterone and combined 17β-estradiol-dydrogesterone preparations in post-menopausal women. Solvay Duphar B.V. (Weesp, The Netherlands). H.102.6005/1; 1992(Data on file)
2. Baird DT, Fraser IS. Blood production and ovarian secretion rates of estradiol-17β and estrone in women throughout the menstrual cycle. J Clin Endocrinol Metab 1974; 38 (6): 1009-17
3. Lievertz RW. Pharmacology and pharmacokinetics of estrogens. Am J Obstet Gynecol 1987 May; 156(5): 1289-93
4. Grodin JM, Siiteri PK, MacDonald PC. Source of estrogen production in postmenopausal women. J Clin Endocrinol Metab 1973; 36: 207-14
5. Goldfien A, Monroe SE, Ovaries. In: Greenspan FS, editor. Basic and clinical endocrinology. 3rd ed. Norwalk (CT): Appleton & Lange, 1991: 442-90
6. Eckernäs S-Å, Grahnén A. A study on multiple dose kinetics of dydrogesterone and dihydrodydrogesterone at 20 mg dydrogesterone and pharmacokinetic interactions between dydrogesterone (20 mg) and estradiol (2 mg) at steady state. Solvay Duphar B.V. (Weesp, The Netherlands). 102.6004; 1990 (Data on file)
7. Kuhl H. Pharmacokinetics of oestrogens and progestogens. Maturitas, 1990; 12: 171-97
8. Walsh BW, Schiff I, Rosner B, et al. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med 1991 Oct 24; 325 (17): 1196-204
9. Selby PL, McGurrigle HHG, Peacock M. Comparison of the effects of oral and transdermal oestradiol administration on oestrogen metabolism, protein synthesis, gonadotrophin release, bone turnover and climacteric symptoms in postmenopausal women. Clin Endocrinol 1989 Mar; 30(3): 241-9
10. van der Mooren MJ, Demacker PNM, Thomas CMG, et al. A 2-year study on the beneficial effects of 17β-oestradiol-dydrogesterone therapy on serum lipoproteins and Lp(a) in postmenopausal women - no additional unfavourable effects of dydrogesterone. Eur J Obstet Gynecol Reprod Biol 1993 Dec 15; 52: 117-23
11. Nichols KC, Schenkel L, Benson H. 17β-Estradiol for postmenopausal estrogen replacement therapy. Obstet Gynecol Survey 1984 Apr; 39 (4 Suppl.): 230-45
12. Hall MH, Webster J. Obstetric and gynaecological disorders. In: Speight TM, Holford NHG, editors. Avecry's drug treatment. 4th ed. Auckland: Adis International. 1997: 683-724
13. Lindsay R. Hormone replacement therapy for prevention and treatment of osteoporosis. Am J Med 1993 Nov 30; 95 Suppl. 5A: 37-9
14. Roux C, Kolta S, Chappard C, et al. Bone effects of dydrogester-one in ovariectomized rats: a biologic, histomorphometric, and densitometric study. Bone 1996 Nov; 19: 463-8
15. Girasole G, Jilka RL, Passeri G, et al. 17β-Estradiol inhibits interleukin-6 production by hone marrow-derived stromal cells and osteoblasts in vitro: a potential mechanism for the antiosteoporotic effect of estrogens. J Clin Invest 1992 Mar; 89: 883-91
16. Verhaar HJJ, Damen CA, Duursma SA, et al. A comparison of the action of progestins and estrogen on the growth and differentiation of normal adult human osteoblast-like cells in vitro. Bone 1994; 15(3): 307-11
17. van Hoof HJC, van der Mooren MJ, Swinkels LMJW, et al. Hormone replacement therapy increases serum 1,25-dihydroxyvitamin D: a 2-year prospective study. Calcif Tissue Int 1994 Dec; 55: 417-9
18. Crook D. Postmenopausal hormone replacement therapy, lipoprotein metabolism, and coronary heart disease. J Cardiovasc Pharmacol 1996; 28 Suppl. 5: S40-5
19. Tikkanen MJ, Nikkila EA, Kuusi T, et al. High density lipoprotein-2 and hepatic lipase: reciprocal changes produced by estrogen and norgestrel. J Clin Endocrinol Metab 1982 Jun; 54 (6): 1113-7
20. Walsh BW, Li H, Sacks FM. Effects of postmenopausal hormone replacement therapy with oral and transdermal estrogen on high density lipoprotein metabolism. J Lipid Res 1994 Nov; 35(11): 2083-93
21. Lobo RA, Speroff L. International consensus conference on postmenopausal hormone therapy and the cardiovascular system. Fertil Steril 1994 Apr; 61: 592-5
22. Stevenson JC, Crook D, Godsland IF, et al. Hormone replacement therapy and the cardiovascular system: nonlipid effects. Drugs 1994; 47 Suppl. 2: 35-41
23. Clarkson TB, Anthony MS, Klein KP. Effects of estrogen treatment on arterial wall structure and function. Drugs 1994; 47 Suppl. 2: 42-51
24. Haenggi W, Linder HR, Birkhueuser MH, et al. Microscopic-findings of the nail-fold capillaries - dependence on menopausal status and hormone replacement therapy. Maturitas 1995; 22: 37-46
25. Englund DE, Johansson DB. Oral versus vaginal absorption in oestradiol in postmenopausal women. Effects of different particles sizes. Ups J Med Sci 1981; 86: 297-307
26. Femoston®. 17β-estradiol + dydrogesterone: product monograph. Weesp. The Netherlands: Solvay Duphar B.V., 1996
27. Balfour JA, Heel RC. Transdermal estradiol: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of menopausal complaints. Drugs 1990; 40 (4): 561-82
28. de Vries MH, van Bemmel P. Multiple dose pharmacokinetics of 1 mg micronized estradiol formulations in healthy postmenopausal women. Solvay Duphar B.V. (Weesp, The Netherlands). H. 102.5010; 1994 (Data on file)
29. Stumpf PG. Pharmacokinctics of estrogen. Obstet Gynecol 1990 Apr; 75 (4 Suppl.): 9S-14S
30. Rozenbaum H. Relationships between chemical structure and biological properties of progestogens. Am J Obstet Gynecol 1982 Mar 15; 142 (6 Pt 2): 719-24
31. Schöler HFL. Biological properties of 9,10-isomeric steroids. I. Progestational activity of 9β, 10α-steroids. Acta Endocrinol 1960; 35: 188-96
32. Marois M. Action d'un progestatif actif pur voie buccale, la dydiogestérone. sur la corne utérine de la lapine. Bull Acad Natl Med 1962; 146: 124-8
33. Tillinger K-G, Diczfalusy E. Progestational activity of stereo-isomeric progesterone-analogues following oral administration in amenorrhoea. Acta Endocrinol 1960; 35: 197-203
34. Lane G, Siddle NC, Ryder TA, et al. Effects of dydrogesterone on the oestrogenized postmenopausal endometrium. Br J Obstet Gynaecol 1986; 93 (1): 55-62
35. Suchowsky GK, Turolla E, Arcari G. Studies of the so-called virilizing effects of steroids in female rat fetuses. Endocrinology 1967 Feb; 80: 255-62
36. Boris A, Stevenson RH, Trmal T. Some studies of the endocrine properties of dydrogesterone. Steroids 1966 Jan; 7: 1-10
37. Marois M. Absence de propriétés masculinisantes ou feminisantes d'un progestatif actif per os, la dydrogestérone chez le rat mâle ou femelle adulte et chez le foetus de rat. Bull Acad Natl Med 1962; 146: 354-64
38. Schöler HFL, de Wachter AM. Evaluation of androgenic properties of progestational compounds in the rat by the female foetal masculinization test. Acta Endocrinol 1961; 38: 128-36
39. Jost A. Maintien de la gestation chez la lapine par un stéréoisomère voisin de la progestérone (6-déhydro-rétroprogestérone). Action sur les foetus. Acta Endocrinol 1963; 43: 539-44
40. Vermorken AJM, Sultan CH, Goos CMAA. Dydrogesterone has no peripheral (anti)-androgenic properties. In Vivo 1987; 1: 167-72
41. van Amsterdam PH, Overmans H, Scherpenisse PM, et al. Dydrogesterone: metabolism in man. Eur J Drug Metab Pharmacokinet 1980; 5(3): 173-84
42. Rijpkema AHM, van der Sanden AA, Ruijs AHC. Effects of post-menopausal oestrogen-progestogen replacement therapy on serum lipids and lipoproteins: a review. Maturitas 1990; 12(3): 259-85
43. Grahnén A, Eckernäs SA. The effects of dydrogesterone on the steady-state pharmacokinetics of estradiol in healthy postmenopausal subjects. Solvay Duphar B.V. (Weesp, The Netherlands). H102.6006; 1994 (Data on file)
44. Belchetz PE. Hormonal treatment of postmenopausal women. N Engl J Med 1994 Apr 14; 330: 1062-71
45. Amy JJ. Femosron®: effects on bone and qualily-of-life. Eur Menopause J 1995; 2 (4 Suppl.): 16-22
46. Paterson MEL. Menopausal symptom relief with cyclic and continuous HRT regimens containing dydrogesterone [abstract]. 7th International Congress on the Menopause; 1993 Jun 20-24; Stockholm, Sweden: 79
47. Stevenson JC. Pathogenesis, prevention and treatment of osteoporosis. Obstet Gynecol 1990 Apr; 75 (4 Suppl.): 36S-41S
48. Consensus Development Conference: diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med 1993 Jun; 94: 646-50
49. Kiel DP, Felson DT, Anderson JJ, et al. Hip fracture and the use of estrogens in postmenopausal women: the Framingham Study. N Engl J Med 1987 Nov 5; 317 (19): 1169-74
50. Naessén T, Persson I, Adami H-O, et al. Hormone replacement therapy and the risk for first hip fracture: a prospective population-based cohort study. Ann Intern Med 1990 Jul 15; 113 (2): 95-103
51. Kanis JA, Johnell O, Gullberg B, et al. Evidence for efficacy of drugs affecting bone metabolism in preventing hip fracture. BMJ 1992 Nov 7; 305: 1124-8
52. Kanis JA. What constitutes evidence for drug efficacy in osteoporosis? Drugs Aging 1993 Sep-Oct; 3: 391-9
53. Grady D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992 Dec 15; 117: 1016-37
54. Josse RG. Prevention and management of osteoporosis: consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada: 3. Effects of ovarian hormone therapy on skeletal and extraskeletal tissues in women. Can Med Assoc J 1996 Oct 1; 155: 929-34
55. Lees B, Pugh M, Siddle N, et al. Changes in hone density in women starting hormone replacement therapy compared with those in women already established on hormone replacement therapy. Osteoporos Int 1995; 5 (5): 344-8
56. Palacios S, Menéndez C. Changes in the BMD during micronized 17β-estradiol and dydrogesterone therapy in the postmenopausal women: a two-year prospective study [poster no. 127]. 11th Congress of European Association of Gynaecologists and Obstetricians; 1996 Jun 19-22; Budapest, Hungary
57. Lippuner K, Haenggi W, Birkhaeuser MH, et al. Prevention of postmenopausal hone loss using tibolone or conventional peroral or transdermal hormone replacement therapy with 17-β estradiol and dydrogesterone. J Bone Miner Res 1997 May; 12 (5): 806-12
58. Bergeron C. Endometrial safety of Femoston®. Eur Menopause J 1995; 2 (4 Suppl.). 4-8
59. Grady D, Gebretsadik T, Kerlikowske K, et al. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol 1995; 85: 304-13
60. AGS Clinical Practice Committee. Counseling postmenopausal women about preventive hormone therapy. J Am Geriatr Soc 1996 Sep; 44: 1120-2
61. Burch DJ, Spowart KJM, Jesinger DK, et al. A dose-ranging study of the use of cyclical dydrogesterone with continuous 17β oestradiol. Br J Obstet Gynaecol 1995 Mar; 102: 243-8
62. Ferenczy A, Gelfand MM. Endometrial histology and bleeding patterns in post-menopausal women taking sequential, combined estradiol and dydrogesterone. Maturitas 1997; 26: 219-26
63. van der Mooren MJ, Hanselaar AGJM, Borm GF, et al. Changes in the withdrawal bleeding pattern and endometrial histology during 17β-estradiol-dydrogesterone therapy in postmenopausal women: a 2 year prospective study. Maturitas 1994 Dec; 20: 175-80
64. Whitehead MI, Hillard TC, Crook D. The role and use of progestogens. Obstel Gynecol 1990 Apr; 75 (4 Suppl): 59S-76S
65. Bush TL, Fried LP, Barrett-Connor E. Cholesterol, lipoproteins, and coronary heart disease in women. Clin Chem 1988; 34 (8 Pt B): B60-70
66. Stevenson JC, Crook D, Godsland IF. Influence of age and menopause on serum lipids and lipoproteins in healthy women. Atherosclerosis 1993; 98: 83-90
67. Wouters MGAJ, Moorrees MThEC, van der Mooren MJ, et al. Plasma homocysteine and menopausal status. Eur J Clin Invest 1995 Nov; 25: 801-5
68. Barrett-Connor E, Bush TL. Estrogen and coronary heart disease in women. JAMA 1991 Apr 10; 265 (14): 1861-7
69. Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med 1991; 20: 47-63
70. Henderson BE, Paganini-Hill A, Ross RK. Decreased mortality in users of estrogen replacement therapy. Arch Intern Med 1991 Jan; 151 (1): 75-8
71. Stampfer MJ, Colditz GA, Willett WC, et al. Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the Nurses' Health Study. N Engl J Med 1991 Sep 12; 325 (11): 756-62
72. Bush TL, Barren-Connor E, Cowan LD, et al. Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the Lipid Research Clinics Program Follow-up Study. Circulation 1987; 75 (6): 1102-9
73. van der Mooren MJ, Wouters MGAJ, Blom HJ, et al. Hormone replacement therapy may reduce high serum homocysteine in postmenopausal women. Eur J Clin Invest 1994 Nov; 24: 733-6
74. Crook D. Multicentre evaluation of 17β oestradiol and dydrogesterone HRT on cardiovascular risk [abstract no. F200]. 8th International Congress on the Menopause; 1996 Nov 3-7; Sydney, Australia, 106
75. Crook D, Godsland IF, Hull J, et al. Hormone replacement therapy with dydrogesterone and 17β-oestradiol: effects on serum lipoproteins and glucose tolerance during 24 month follow up. Br J Obstet Gynaecol 1997 Mar; 104: 298-304
76. Gelfand M, Fugère P, Bissonnette F. Cardiovascular risk factors during sequentially combined 17β oestradiol and dydrogesterone (Femoston®); results from a one-year study in postmenopausal women. Maturitas 1997; 26: 125-32
77. Hänggi W, Lippuner K, Riesen W, et al. Long term influence of different postmenopausal hormone replacement regimens on serum lipids and lipoprotein(a): a randomised study. Br J Obstet Gynaecol 1997 Jun; 104: 708-17
78. Drexel H, Amann FW, Rentsch K, et al. Relation of the level of high-density lipoprotein subfractions to the presence and extent of coronary artery disease. Am J Cardiol 1992 Aug 15; 70: 436-40
79. van der Mooren MJ, de Graaf J, Demacker PN, et al. Changes in the low-density lipoprotein profile during 17β-estradiol-dydrogesterone therapy in postmenopausal women. Metabolism 1994 Jul; 43: 799-802
80. Gaspard UJ, Wéry O, Scheen AJ, et al. Carbohydrate melabolism is not impaired in postmenopausal women using micronized estradiol and dydrogesterone for twelve months [abstract no. 260]. 7th International Congress on the Menopause; 1993 Jun 20-24; Stockholm, Sweden, 65
81. van der Mooren MJ. The influence of postmenopausal oestradiol-dydrogesterone therapy on blood pressure [abstract no. F179]. 8th International Congress on the Menopause; 1996 Nov 3-7; Sydney, Australia
82. Hanggi W, Lippuner K, Jaeger P, et al. The influence of postmenopausal replacement therapy on body composition [abstract]. Osteoporos Int 1996; 6 Suppl. 1: 230
83. Meijer S, Hamerlynck JVTH, Sauerwein HP. Effects of postmenopausal use of 17-́-oestradiol and dydrogesterone on body composition (fat and water) [abstract]. 7th International Congress on the Menopause; 1993 Jun 20-24; Stockholm, Sweden: 391
84. Jacobs S, Hillard TC. Hormone replacement therapy in the aged: a state of the art review. Drugs Aging 1996 Mar; 8: 193-213
85. Mauvais-Jarvis P, Kuttenn F, Compel A. Estradiol/progesterone interaction in normal and pathologic breast cells. Ann N Y Acad Sci 1986; 464: 152-67
86. Bergkvist L, Persson I. Hormone replacement therapy and breast cancer: a review of current knowledge. Drug Saf 1996 Nov; 15: 360-70
87. Hormone replacement therapy (HRT) and breast cancer risk. International Medical Benefit/Risk Foundation Workshop (London, October 29-30, 1992). Pharmacoepidemiol Drug Saf 1993; 2: 103-5
88. Henrich JB. The postmenopausal estrogen/breast cancer controversy. JAMA 1992 Oct 14; 268: 1900-2
89. Brinton LA, Hoover R, Fraumeni Jr JF. Menopausal oestrogens and breast cancer risk: an expanded case-control study. Br J Cancer 1986; 54: 825-32
90. Steinberg KK, Thacker SB, Smith SJ, et al. A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer. JAMA 1991 April 17; 265 (15): 1985-90
91. Colditz GA, Stampfer MJ, Willett WC, et al. Type of postmenopausal hormone use and risk of breast cancer: 12-year follow-up from the Nurses' Health Study. Cancer Causes Control 1992 Sep; 3: 433-9
92. Bergkvist L, Adami H-O, Persson I, et al. The risk of breast cancer after estrogen and estrogen-progestin replacement. N Engl J Med 1989 Aug 3; 321 (5): 293-7
93. Gambrell Jr RD, Maier RC, Sanders BI. Decreased incidence of breast cancer in postmenopausal estrogen-progestogen users. Obstet Gynecol 1983 Oct; 62 (4): 435-43
94. Hartmann BW, Huber JC. The mythology of hormone replacement therapy. Br J Obstet Gynaecol 1997 Feb; 104: 163-8
95. Carr BR, Wilson JD. Disorders of the ovary and female reproductive tract. In: Isselbacher KJ, Braunwald E, Wilson JD, et al., editors. Harrison's principles of internal medicine. 13th ed. Vol. 2. New York: McGraw-Hill, Inc., 1994: 2017-36
96. Mashchak CA, Lubo RA, Dozono-Takano R, et al. Comparison of pharmacodynamic properties of various eslrogen formulations. Am J Obstet Gynecol 1982 Nov 1; 144 (5): 511-8
97. Gelfand MM, Fugere P, Bissonnette F, et al. Conjugated estrogens combined with sequential dydrogesterone or medroxy-progesterone acetate in postmenopausal women: effects on lipoproteins, glucose tolerance, endometrial histology, and bleeding. Menopause 1997; 4(1): 10-8
98. Crook D, Cust MP, Gangar KF, et al. Comparison of transdermal and oral estrogen-progestin replacement therapy: effects on serum lipids and lipoproteins. Am J Obstet Gynecol 1992 Mar; 166 (3): 950-5
99. Balfour JA, McTavish D. Transdermal estradiol: a review of its pharmacological profile, and therapeutic potential in the prevention of postmenopausal ostcoporosis. Drugs Aging 1992; 2 (6): 487-507
100. Falkeborn M, Persson I, Adami H-O, et al. The risk of acute myocardial infarction after oestrogen and oestrogen-progestogen replacement. Br J Obstet Gynaecol 1992 Oct; 99: 821-8
101. Grodstein F, Stampfer MJ, Manson JE, et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 1996 Aug 15; 335 (7): 453-61
102. Psaty BM, Heckbert SR, Atkins D, et al. The risk of myocardial infarction associated with the combined use of estrogens and progestins in postmenopausal women. Arch Intern Med 1994 Jun 27; 154 (12): 1333-9
103. Col NF, Eckman MH, Karas RH, et al. Patient-specific decisions about hormone replacement therapy in postmenopausal women. JAMA 1997 Apr 9; 277 (14): 1140-7
104. Al-Azzawi F, Habiba M. Regular bleeding on hormone replacement therapy: a myth? Br J Obstet Gynaecol 1994 Aug; 101: 661-2
105. Hahn RG. Compliance considerations with estrogen replacement: withdrawal bleeding and other factors. Am J Obstet Gynecol 1989 Dec; 161 (6 Pt 2): 1854-8
106. Ferguson KJ, Hoegh C, Johnson S. Estrogen replacement therapy: a survey of women's knowledge and attitudes. Arch Intern Med 1989 Jan; 149: 133-6
107. Ryan PJ, Harrison R, Blake CM, et al. Compliance with hormone replacement therapy (HRT) alter screening for post menopausal osteoporosis. Br J Obstet Gynaecol 1992 Apr; 99: 325-8